| Friday, October 31 |
| 6:00 am - 6:00 pm |
Registration Open |
| 7:00 am - 8:00 am |
Continental Breakfast |
| 7:45 am - 7:50 am |
Welcome and Introduction |
| 7:50 am - 8:15 am |
Keynote Address
Michael Karin, PhD, University of California, San Diego
|
| 8:15 am - 11:30 am |
State of the Science Plenary Sessions |
| 8:15 am - 8:45 am |
Defining Inflammation
|
| 8:45 am - 9:15 am |
Genetic Polymorphisms and Factors which Modulate Inflammation and Cancer
|
| 9:15 am - 9:45 am |
Animal Models of Cancer and Inflammation
| Co-Chairs: |
Lisa M. Coussens, PhD, University of California, San Francisco
Michael Karin, PhD, University of California, San Diego |
|
| 9:45 am - 10:00 am |
Break |
| 10:00 am - 10:30 am |
Causes and Molecular Targets in Cancer and Inflammation
| Co-Chairs: |
Michael T. Lotze, MD, University of Pittsburgh Cancer Institute
TBC |
|
| 10:30 am - 11:00 am |
Current Clinical Evidence for Targeting Inflammation to Prevent Cancer
| Co-Chairs: |
Steven Dubinett, MD, University of California, Los Angeles
TBC |
|
| 11:00 am - 11:30 am |
Novel Therapeutics and Clinical Trial Development to Treat Cancer
| Co-Chairs: |
Arthur M. Krieg, MD, Pfizer
George J. Weiner, MD, University of Iowa |
|
| 11:30 am - 12:00 pm |
Lunch |
| 12:00 pm - 1:30 pm |
Concurrent Breakout Sessions
(limited space available, pre-registration and ticket required) |
| |
Breakout Session 1: Defining Inflammation
Breakout Session 2: Genetic Polymorphisms and Factors which Modulate Inflammation and Cancer
Breakout Session 3: Animal Models of Cancer and Inflammation.
Breakout Session 4: Causes and Molecular Targets in Cancer and Inflammation
Breakout Session 5. Current Clinical Evidence for Targeting Inflammation to Prevent Cancer
Breakout Session 6. Novel Therapeutics and Clinical Trial Development to Treat Cancer
|
| 12:00 pm - 1:30 pm |
Concurrent Group Lecture: Abstract Presentations
|
| 12:00 pm - 12:15 pm |
Abstract 1 |
| 12:15 pm - 12:30 pm |
Abstract 2 |
| 12:30 pm - 12:45 pm |
Abstract 3 |
| 12:45 pm - 1:00 pm |
Abstract 4 |
| 1:00 pm - 1:15 pm |
Abstract 5 |
| 1:15 pm - 1:30 pm |
Abstract 6 |
| 1:30 pm - 1:45 pm |
Break |
| 1:45 pm - 2:45 pm |
Plenary Session: Perspectives on Anti-inflammatory Therapy |
| 1:45 pm - 2:05 pm |
FDA Perspective: Speaker TBC |
| 2:05 pm - 2:25 pm |
Industry Perspective: Speaker TBC |
| 2:25 pm - 2:45 pm |
Legal Perspective: Speaker TBC |
| 2:45 pm - 5:45 pm |
Reporting Session/Panel Discussion
Moderator: Michael T. Lotze, MD, University of Pittsburgh Cancer Institute |
| 2:45 pm - 3:15 pm |
Breakout 1 Report: Defining Inflammation |
| 3:15 pm - 3:45 pm |
Breakout 2 Report: Genetic Polymorphisms and Factors which Modulate Inflammation and Cancer |
| 3:45 pm - 4:15 pm |
Breakout 3 Report: Animal Models of Cancer and Inflammation. |
| 4:15 pm - 4:45 pm |
Breakout 4 Report: Causes and Molecular Targets in Cancer and Inflammation |
| 4:45 pm - 5:15 pm |
Breakout 5 Report: Current Clinical Evidence for Targeting Inflammation to Prevent Cancer |
| 5:15 pm - 5:45 pm |
Breakout 6 Report: Novel Therapeutics and Clinical Trial Development to Treat Cancer |
| 5:45 pm - 6:00 pm |
Closing Comment and Future Plans
Lisa M. Coussens, PhD, University of California, San Francisco
|
